| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/02/2003 | CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor |
| 04/02/2003 | CN1407978A Polyhydroxystilbenes and stibene oxides as antisoriatic agents and protein kinase inhibitors |
| 04/02/2003 | CN1407973A Butyne diol derivatives |
| 04/02/2003 | CN1407971A Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 04/02/2003 | CN1407901A Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| 04/02/2003 | CN1407900A Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1) |
| 04/02/2003 | CN1407896A Exemestane for first-line treatment of breast cancer |
| 04/02/2003 | CN1406630A Composite enzyme reacting liquid |
| 04/02/2003 | CN1406629A Vaccin of heterogenous blood vessel endothetial cell growth factor and preparing process thereof |
| 04/02/2003 | CN1406626A Natural anticancer preparation and process and use thereof |
| 04/02/2003 | CN1406590A Natural Chinese medicine for treating cancer and preparation thereof |
| 04/02/2003 | CN1406583A Usage of indole derivatives for treating tumours |
| 04/02/2003 | CN1406582A Anti-cancer salvithin injection |
| 04/02/2003 | CN1104434C Optical pure analogs of camptothecinum and composition and use thereof |
| 04/02/2003 | CN1104432C Pyrrole triazines and pyrimidine compound |
| 04/02/2003 | CN1104428C Substitued benzocycloheptapyridine useful ad inhibitors of Farnesyl protein transferase |
| 04/02/2003 | CN1104427C Tricyclic inhibitors of farnesyl protein transferase |
| 04/02/2003 | CN1104421C Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
| 04/02/2003 | CN1104420C Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl) phenyl)-4-methyl-2,5-imidazolidin-1-yl) acetylamino)-3-phenyl propionate |
| 04/02/2003 | CN1104238C Enteric-coated pharmaceutical compositions of mycophenolate |
| 04/02/2003 | CN1104202C Aglucone isoflavone enriched vegetable protein extract and isolate and process for producing |
| 04/02/2003 | CA2424540A1 Propionic acid derivatives with ppar-alpha activating properties |
| 04/01/2003 | WO2002029054A1 Novel protein, process for producing the same and use thereof |
| 04/01/2003 | US6541661 Inhibitors of histone deacetylase |
| 04/01/2003 | US6541638 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction |
| 04/01/2003 | US6541623 Sepsis shock therapy; rheumatic diseases; antiinflammatory agents; nucleotide sequence detector |
| 04/01/2003 | US6541619 Genetic engineering; transforming Escherichia culture product; anticancer agent |
| 04/01/2003 | US6541518 Preventing pathogens in blood plasma and for enhancing the production of cryoprecipitate from plasma by adding a low molecular weight carboxylic acid or salt to the plasma, preferably trisodium citrate |
| 04/01/2003 | US6541508 Water solubility; prodrug containing polyether oligomer |
| 04/01/2003 | US6541505 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. |
| 04/01/2003 | US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 04/01/2003 | US6541496 Inhibitors of IMPDH enzyme |
| 04/01/2003 | US6541493 Type A, B, C and D crystals of said compound; excellent in stability, and has advantages in handling, storage, and pharmaceutical preparation. |
| 04/01/2003 | US6541492 Thiazole derivatives as PPAR gamma ligands |
| 04/01/2003 | US6541491 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors |
| 04/01/2003 | US6541490 Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt |
| 04/01/2003 | US6541489 Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 |
| 04/01/2003 | US6541485 Urea substituted imidazoquinolines |
| 04/01/2003 | US6541483 Acridone-derived compounds useful as antineoplastic and antiretroviral agents |
| 04/01/2003 | US6541481 Substituted bicyclic derivatives useful as anticancer agents |
| 04/01/2003 | US6541475 2-nitrostyryl-1-(naphthylmethyl)sulfone for example |
| 04/01/2003 | US6541474 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia |
| 04/01/2003 | US6541468 Treating Alzheimer's disease by inhibiting in a subject hyperphosphoralation characteristic of Alzheimer's disease by a kinase the compound |
| 04/01/2003 | US6541463 Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use |
| 04/01/2003 | US6541462 Sphingomyelin enhancement of tumor therapy |
| 04/01/2003 | US6541253 Diagnostics and therapy of diseases associated with HHV-8 infections |
| 04/01/2003 | US6541214 N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| 04/01/2003 | US6541212 Anticancer agents |
| 04/01/2003 | US6541039 For use in tumor therapy by hyperthermia |
| 04/01/2003 | US6541015 Water soluble prodrug with a biologically active agent link trapped in a hydrogel and controllably released by diffusion |
| 04/01/2003 | US6540977 Cyanidin compositions and therapeutic and diagnostic uses therefor |
| 04/01/2003 | CA2424777A1 Novel protein, process for producing the same and use thereof |
| 04/01/2003 | CA2163539C N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes |
| 04/01/2003 | CA2102129C Growth hormone antagonists |
| 03/28/2003 | CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue |
| 03/28/2003 | CA2404045A1 Use of coagulation factor vii-activating protease for the prophylaxis and therapy of vasoproliferative disorders |
| 03/27/2003 | WO2003025542A2 Immune response associated proteins |
| 03/27/2003 | WO2003025200A2 Methods of using 22417, a novel human aminoprotease family member |
| 03/27/2003 | WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 03/27/2003 | WO2003025191A2 Pseudotyped retroviral vector system |
| 03/27/2003 | WO2003025178A1 Novel protein and dna thereof |
| 03/27/2003 | WO2003025177A2 Sequences involved in phenomena of tumour suppression, tumour reversion, adoptosis and/or resistance to viruses and the use thereof as medicaments |
| 03/27/2003 | WO2003025176A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 03/27/2003 | WO2003025171A2 Modulation of retinoic acid receptor gene expression and therapeutic uses thereof |
| 03/27/2003 | WO2003025168A1 Novel protein and dna thereof |
| 03/27/2003 | WO2003025162A2 Regulation of human prolyl 4-hydroxylase alpha subunit precursor |
| 03/27/2003 | WO2003025151A2 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression |
| 03/27/2003 | WO2003025149A2 Cell populations which co-express cd49c and cd90 |
| 03/27/2003 | WO2003025131A2 Protein modification and maintenance molecules |
| 03/27/2003 | WO2003025129A2 Neurotransmission-associated proteins |
| 03/27/2003 | WO2003025127A2 Chromogenic in situ hybridization methods, kits, and compositions |
| 03/27/2003 | WO2003025121A2 Igf-binding protein-derived peptide or small molecule |
| 03/27/2003 | WO2003025119A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 03/27/2003 | WO2003025019A1 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 03/27/2003 | WO2003025017A1 Cytokine receptor |
| 03/27/2003 | WO2003024997A1 Telomerase inhibitory peptides and uses thereof |
| 03/27/2003 | WO2003024993A2 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
| 03/27/2003 | WO2003024969A1 Tyrosine kinase inhibitors |
| 03/27/2003 | WO2003024967A2 Indolizines as kinase protein inhibitors |
| 03/27/2003 | WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity |
| 03/27/2003 | WO2003024950A1 Coumarin derivative |
| 03/27/2003 | WO2003024949A1 Dna-pk inhibitors |
| 03/27/2003 | WO2003024940A1 Bifunctional chelating agent for actinium |
| 03/27/2003 | WO2003024936A1 Substituted pyrazolo compounds for the treatment of inflammation |
| 03/27/2003 | WO2003024935A2 Substituted pyrazolyl compounds for the treatment of inflammation |
| 03/27/2003 | WO2003024928A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 03/27/2003 | WO2003024926A2 Methods and compositions of novel triazine compounds |
| 03/27/2003 | WO2003024924A1 Novel compounds and compositions as cathepsin inhibitors |
| 03/27/2003 | WO2003024921A1 Alkyl urea retinoid agonists i |
| 03/27/2003 | WO2003024920A1 Substituted urea retinoid agonists ii |
| 03/27/2003 | WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY |
| 03/27/2003 | WO2003024529A1 Simplified sarcodictyn derivatives as anti-tumor agents |
| 03/27/2003 | WO2003024485A1 REMEDIES FOR DISEASES CAUSED BY β-AMYLOIDS CONTAINING 2-100β INHIBITOR AS THE ACTIVE INGREDIENT |
| 03/27/2003 | WO2003024481A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 03/27/2003 | WO2003024480A2 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| 03/27/2003 | WO2003024475A1 Water-insoluble sustained release compositions, preparations thereof and process for producing the same |
| 03/27/2003 | WO2003024474A2 Anti-inflammatory agent |
| 03/27/2003 | WO2003024465A2 Use of extracts of the genus cimicifuga as organoselective medicines |
| 03/27/2003 | WO2003024459A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 03/27/2003 | WO2003024448A2 Inhibitors of histone deacetylase |